Overview

Useful For
Monitoring dietary therapy of patients with galactosemia due to deficiency of galactose-1-phosphate uridylyltransferase or uridine diphosphate galactose-4-epimerase

Genetics Test Information
Galactose-1-phosphate uridylyltransferase (GALT) deficiency is the most common cause of galactosemia and requires lifelong restriction of dietary galactose.

Galactose-1-phosphate is elevated in patients with galactosemia due to GALT deficiency or uridine diphosphate galactose-4-epimerase (GALE) deficiency, therefore is a suitable analyte for monitoring dietary compliance.

Testing Algorithm
See Galactosemia Testing Algorithm in Special Instructions

Special Instructions
- Galactosemia Testing Algorithm
- Biochemical Genetics Patient Information
- Galactosemia-Related Test List

Method Name
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

NY State Available
Yes

Specimen

Specimen Type
Whole Blood EDTA

Advisory Information
This test is used to monitor dietary therapy of patients with galactosemia due to deficiency of galactose-1-phosphate uridylyltransferase (GALT) or uridine diphosphate galactose-4-epimerase (GALE).

This test is not appropriate for the diagnosis of galactosemia. The preferred test to evaluate for possible diagnosis of galactosemia, routine carrier screening, and follow-up of abnormal newborn screening results is GCT / Galactosemia Reflex, Blood.

This test is not appropriate for the diagnosis of epimerase deficiency, the preferred test to evaluate this deficiency is GALE / UDP-Galactose 4‘ Epimerase, Blood.

Necessary Information
Biochemical Genetics Patient Information(T602) is recommended, but not required, to be filled out and sent with the specimen to aid in the interpretation of test results.

Specimen Required
Multiple whole blood tests for galactosemia can be performed on 1 specimen. Prioritize order of testing when
submitting specimens. See Galactosemia-Related Test List in Special Instructions for a list of tests that can be ordered together.

**Patient Preparation:** Specimens collected following a meal can exhibit postprandial elevations. For infants, collect a specimen immediately prior to feeding to avoid this.

**Container/Tube:**

**Preferred:** Lavender top (EDTA)

**Acceptable:** Green top (sodium heparin)

**Specimen Volume:** 3 mL

**Forms**

1. Biochemical Genetics Patient Information (T602) is recommended, see Special Instructions.

2. If not ordering electronically, complete, print, and send an Inborn Errors of Metabolism Test Request (T798) with the specimen.

**Specimen Minimum Volume**

2 mL

**Reject Due To**

| Gross hemolysis | Reject |

**Specimen Stability Information**

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole Blood EDTA</td>
<td>Refrigerated</td>
<td>72 hours</td>
<td></td>
</tr>
</tbody>
</table>

**Clinical and Interpretive**

**Clinical Information**

Galactosemia is an autosomal recessive disorder that results from a deficiency of any 1 of the 3 enzymes catalyzing the conversion of galactose to glucose: galactose-1-phosphate uridyltransferase (GALT), galactokinase (GALK), and uridine diphosphate galactose-4-epimerase (GALE). Galactose-1-phosphate (Gal-1-P) accumulates in the erythrocytes of patients with galactosemia due to either GALT or GALE deficiency. The quantitative measurement of Gal-1-P Â is useful for monitoring compliance with dietary therapy for either deficiency. Gal-1-P is thought to be the causative factor for development of liver disease in these patients and, because of this, patients should maintain low levels and be monitored on a regular basis. The concentration of Gal-1-P in erythrocytes is the most sensitive index of dietary control.

GALT deficiency is the most common cause of galactosemia and is often referred to as classic galactosemia. The complete or near-complete deficiency of GALT enzyme is life-threatening if left untreated. Complications in the neonatal period include failure to thrive, liver failure, sepsis, and death.
Galactosemia due to GALT deficiency is treated by a galactose-restricted diet, which allows for rapid recovery from the acute symptoms and a generally good prognosis. Despite adequate treatment from an early age, individuals with galactosemia remain at increased risk for developmental delays, speech problems, and abnormalities of motor function. Females with galactosemia are at increased risk for premature ovarian failure. Based upon reports by newborn screening programs, the frequency of classic galactosemia in the United States is approximately 1 in 30,000, although literature reports range from 1 in 10,000 to 1 in 60,000 live births.

Epimerase deficiency galactosemia can be categorized into 3 types: generalized, peripheral, and intermediate. Generalized epimerase deficiency galactosemia results in profoundly decreased enzyme activity in all tissues, whereas peripheral epimerase deficiency galactosemia results in decreased enzyme activity in red and white blood cells, but normal enzyme activity in all other tissues. This is compared with intermediate epimerase deficiency galactosemia, which results in decreased enzyme activity in red and white blood cells and less than 50% of normal enzyme levels in other tissues.

Clinically, infants with generalized epimerase deficiency galactosemia develop symptoms such as liver and renal dysfunction and mild cataracts when on a normal milk diet, while infants with peripheral or intermediate epimerase deficiency galactosemia do not develop any symptoms. Generalized epimerase deficiency galactosemia is treated by a galactose- and lactose-restricted diet, which can improve or prevent the symptoms of renal and liver dysfunction and mild cataracts. Despite adequate treatment from an early age, individuals with generalized epimerase deficiency galactosemia remain at increased risk for developmental delay and intellectual disability. Unlike patients with classic galactosemia resulting from a GALT deficiency, females with generalized epimerase deficiency galactosemia experience normal puberty and are not at increased risk for premature ovarian failure. Based upon reports by newborn screening programs, the frequency of epimerase deficiency galactosemia in the United States ranges from approximately 1 in 6700 in African American infants to 1 in 70,000 in infants of European ancestry.

See Galactosemia Testing Algorithm in Special Instructions.

**Reference Values**

Reference interval (normal range) : \(< or =0.9 \text{ mg/dL}\)

Therapeutic range: \(< or =4.9 \text{ mg/dL}\)

**Interpretation**

The concentration of galactose-1-phosphate (Gal-1-P) is provided along with reference values for patients with galactosemia and normal controls. The recommended Gal-1-P goal for patients with galactosemia is less than or equal to 4.9 mg/dL.

See Galactosemia Testing Algorithm in Special Instructions for additional information.

**Cautions**

No significant precautionary statements.

**Clinical Reference**


Test Definition: GAL1P
Galactose-1-Phosphate, RBC

Performance

Method Description
Packed RBCs are diluted with cold water and vortexed to lyse the cells, creating a hemolysate. The hemolysate is extracted with acetonitrile/methanol containing internal standard and then is centrifuged prior to injection onto a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. The ratio of the extracted peak area of Gal-1-P to its internal standard (13)C2-Gal-1-P as determined by LC-MS/MS is used to calculate the concentration of analyte, in mg/dL, in the sample. (Unpublished Mayo method)

PDF Report
No

Day(s) and Time(s) Test Performed
Thursday; 8 a.m.

Analytic Time
8 days

Maximum Laboratory Time
15 days

Specimen Retention Time
1 month

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
84378

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAL1P</td>
<td>Galactose-1-Phosphate, RBC</td>
<td>2312-7</td>
</tr>
<tr>
<td>Result ID</td>
<td>Test Result Name</td>
<td>Result LOINC Value</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>24101</td>
<td>Galactose-1-Phosphate, RBC</td>
<td>2312-7</td>
</tr>
</tbody>
</table>